Approximately 50 percent of people who are prescribed chronic glucocorticoid therapy for rheumatoid arthritis will eventually have an osteoporotic fracture. The use of glucocorticoid medications can lead to a reduction in bone formation.
Eli Lilly and Company's drug Forteo has been FDA approved as a new use to treat osteoporosis along with chronic glucocorticoid therapy drugs. Lily said Forteo is supposed to counter the effects of these glucocorticoid therapy drugs while stimulating bone formation.
Lilly provided data from a clinical study demonstrating the effectiveness of the product.